PXD063393-1

PXD063393 is an original dataset announced via ProteomeXchange.

Title	PAK1 activation as a common mechanism of endocrine therapy resistance in luminal A breast cancer models
Description	Breast cancer is a highly heterogeneous disease, representing the most frequent malignancy and the second leading cause of cancer-related mortality in women worldwide. Among breast cancer subtypes, estrogen receptor-positive (ER+) tumors are often treated with endocrine therapies such as Tamoxifen or aromatase inhibitors (AIs), aimed at disrupting estrogen signaling. While these therapies are initially effective, up to 40% of patients eventually develop resistance, leading to disease relapse. The kinase p21-activated kinase 1 (PAK1), a key regulator of multiple oncogenic signaling pathways, has been previously implicated in resistance to Tamoxifen. However, its role in driving resistance to aromatase inhibitors remains unclear. In this study, we demonstrate that PAK1 contributes to resistance in both Tamoxifen and AI therapy contexts. Using global phospho-proteomic profiling, we observed elevated PAK1 activity in cell line models resistant to both therapies, with further increases following EGF stimulation. Notably, PAK1 inhibition effectively reduced cell proliferation in both resistance models, albeit with distinct effects on downstream PAK1 substrates. Our findings position PAK1 as a common mediator of resistance to endocrine therapies and offer valuable insights into the specific signaling networks involved in this process. These results suggest that targeting PAK1 may present a novel therapeutic strategy to overcome resistance in ER+ breast cancer, enhancing the efficacy of both Tamoxifen and AI treatments.
HostingRepository	PRIDE
AnnounceDate	2026-02-14
AnnouncementXML	Submission_2026-02-14_09:59:12.052.xml
DigitalObjectIdentifier
ReviewLevel	Peer-reviewed dataset
DatasetOrigin	Original dataset
RepositorySupport	Unsupported dataset by repository
PrimarySubmitter	Luisa Schwarzmüller
SpeciesList	scientific name: Homo sapiens (Human); NCBI TaxID: NEWT:9606;
ModificationList	iodoacetamide derivatized residue
Instrument	Q Exactive

Revision	Datetime	Status	ChangeLog Entry
0	2025-04-28 06:34:41	ID requested
⏵ 1	2026-02-14 09:59:12	announced

Dataset with its publication pending

submitter keyword: endocrine therapy,Breast cancer, therapy resistance, phosphoproteomics

Prof. Dr. Stefan Wiemann
contact affiliation	Molekulare Genomanalyse (B050) Deutsches Krebsforschungszentrum Im Neuenheimer Feld 580 69120 Heidelberg Germany
contact email	s.wiemann@dkfz.de
lab head
Luisa Schwarzmüller
contact affiliation	German Cancer Research Center (DKFZ)
contact email	luisa.schwarzmueller@dkfz.de
dataset submitter

Dataset FTP location NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2026/02/PXD063393

PRIDE project URI

• PRIDE
  1. PXD063393
     1. Label: PRIDE project
     2. Name: PAK1 activation as a common mechanism of endocrine therapy resistance in luminal A breast cancer models